Outcomes
migraine, Headache, Migraine
MIGRAINE, SECONDARY, MIGRAINE, ADVERSE EVENT
Changes from baseline in the number of monthly migraine days (MMDs) and the percentages of patients achieving ≥ 50% reduction in MMDs (≥ 50% response) and ≥ 75% reduction in MMDs (≥ 75% response) during Weeks 25–36, 37–48, 49–60, and 61–72 were predefined secondary study endpoints. These endpoints were derived from data collected via the eDiary. The change from baseline in the 6-item Headache Impact Test (HIT-6) total score at Weeks 36, 48, 60, and 72 was also a predefined secondary endpoint.Predefined exploratory endpoints included the change from baseline in the percentage of migraine attacks of severe intensity (Weeks 25–36, 37–48, 49–60, and 61–72); change from baseline in monthly acute migraine medication use; patient-identified most bothersome symptom (PI-MBS) score (Weeks 36, 48, 60, and 72); Patient Global Impression of Change (PGIC) score (Weeks 36, 48, 60, and 72); change from baseline in Migraine-Specific Quality of Life questionnaire (MSQ) subscores (Weeks 36, 48, 60, and 72); change from baseline in EQ-5D-5L visual analog scale (VAS) score (Weeks 36, 48, 60, and 72); and change from baseline in Work Productivity and Impairment, adapted for Migraine (WPAI:M) subscores for absenteeism, presenteeism, work productivity loss, and activity impairment (Weeks 36, 48, 60, and 72). Patient-reported outcomes are described in the The safety/tolerability of long-term eptinezumab treatment was assessed identically to the primary report and included adverse event monitoring, clinical laboratory testing, physical examinations, electrocardiograms, the Columbia–Suicide Severity Rating Scale, and blood sampling for anti-drug antibody assessment [